* To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load as triage markers in post-menopausal HPV-screen-positive women aged 50-64 years in the organized screening program to predict the risk of developing CIN2+. (work package 1) * To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load six months after cervical excision to predict the long-term risk of residual/recurrent CIN2+ lesions among women aged 23-64 (work-package 2)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The number of women with CIN2+ diagnosed in either cervical biopsies or cone biopsy
Timeframe: at baseline ( within 3 months after index sample)
The number of women with CIN2+ diagnosed in either cervical biopsies or cone biopsy
Timeframe: at follow-up ( 1.5 years after index sample)
The number of women with CIN3+ diagnosed in either cervical biopsies or cone biopsy
Timeframe: at baseline ( within 3 months after index sample)
The number of women with CIN3+ diagnosed in either cervical biopsies or cone biopsy
Timeframe: at follow-up (1.5 years after index sample)